Startup profile · funding coverage
Tmunity Therapeutics
Next-generation CAR-T cell therapy biotech from Penn Medicine.
Stage
acquired
Status
acquired
Coverage
full
Why Tmunity Therapeutics is interesting
Carl June/Bruce Levine cell-therapy lineage — a16z-led $75M B before Gilead/Kite buyout.
Key facts
- Series B (2019): $75M led by a16z; Kleiner Perkins participated (a16z announcement)
- Exit (2023): acquired by Gilead/Kite (Gilead press)
Investors in our directory
Funds linked from Tmunity Therapeutics's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Tmunity Therapeutics's financing or category context.
Last updated: 2026-07-24